title: Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.
abstract: Central nervous system glucagon-like peptide-1-(7-36) amide (GLP-1) administration has been reported to acutely reduce food intake in the rat. We here report that repeated intracerebroventricular (i.c.v.) injection of GLP-1 or the GLP-1 receptor antagonist, exendin-(9-39), affects food intake and body weight. Daily i.c.v. injection of 3 nmol GLP-1 to schedule-fed rats for 6 days caused a reduction in food intake and a decrease in body weight of 16 +/- 5 g (P < 0.02 compared with saline-injected controls). Daily i.c.v. administration of 30 nmol exendin-(9-39) to schedule-fed rats for 3 days caused an increase in food intake and increased body weight by 7 +/- 2 g (P < 0.02 compared with saline-injected controls). Twice daily i.c.v. injections of 30 nmol exendin-(9-39) with 2.4 nmol neuropeptide Y to ad libitum-fed rats for 8 days increased food intake and increased body weight by 28 +/- 4 g compared with 14 +/- 3 g in neuropeptide Y-injected controls (P < 0.02). There was no evidence of tachyphylaxis in response to i.c.v. GLP-1 or exendin-(9-39). GLP-1 may thus be involved in the regulation of body weight in the rat.
authors.affiliation: Imperial College School of Medicine Endocrine Unit, Hammersmith Hospital, London, United Kingdom.
authors.forename: K
authors.initials: K
authors.lastname: Meeran
authors.forename: D
authors.initials: D
authors.lastname: O'Shea
authors.forename: C M
authors.initials: CM
authors.lastname: Edwards
authors.forename: M D
authors.initials: MD
authors.lastname: Turton
authors.forename: M M
authors.initials: MM
authors.lastname: Heath
authors.forename: I
authors.initials: I
authors.lastname: Gunn
authors.forename: S
authors.initials: S
authors.lastname: Abusnana
authors.forename: M
authors.initials: M
authors.lastname: Rossi
authors.forename: C J
authors.initials: CJ
authors.lastname: Small
authors.forename: A P
authors.initials: AP
authors.lastname: Goldstone
authors.forename: G M
authors.initials: GM
authors.lastname: Taylor
authors.forename: D
authors.initials: D
authors.lastname: Sunter
authors.forename: J
authors.initials: J
authors.lastname: Steere
authors.forename: S J
authors.initials: SJ
authors.lastname: Choi
authors.forename: M A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: S R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D002149:Energy Intake / Q000187:drug effects; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D007276:Injections, Intraventricular; D008297:Male; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018377:Neurotransmitter Agents; D010446:Peptide Fragments; C055453:glucagon-like peptide 1 (7-36)amide; C083773:exendin (9-39); D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon